ArticleMovement disorders clinical practice2026
Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is the second most common neurodegenerative disease. Symptomatic treatment is based on dopaminergic replacement. With disease progression, the initial benefit of levodopa becomes inconsistent, and motor complications emerge. One strategy used to maintain stable levodopa plasma levels throughout the day is the use of opicapone, a catechol-O-methyltransferase (COMT) inhibitor. Despite its efficacy, there is variability in the therapeutic response and development of adverse events to this drug. Variants in the COMT and UGT1A genes have been proposed to modulate the effect of this medication, either positively or negatively.
objectiveTo assess the impact of COMT and UGT1A genetic variants on opicapone efficacy in PD patients.
methodsWe conducted a retrospective study of 237 PD patients treated with opicapone between May 2017 and June 2025. The COMT rs4818, rs4680, rs4633 and rs6269, and UGT1A rs1105880 SNPs were genotyped. Three established COMT activity haplotypes (low, medium, and high) were evaluated alongside clinical characteristics and treatment response.
resultsCOMT rs4818 and rs6269 heterozygosity was associated with improvement in motor fluctuations. The low activity COMT haplotype was associated with improved motor fluctuations, whereas the medium activity COMT haplotype showed only a nominal protective association against dyskinesia worsening. The UGT1A rs1105880 dominant model was significantly associated with improvement in motor fluctuations. No variant was associated with treatment discontinuation.
conclusionsThese results suggest that COMT and UGT1A genotyping may contribute to personalized therapy in PD, although prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.